Fetterman pushes for Medicare to cover GLP-1s

Senator John Fetterman explains how GLP-1 drugs changed his life

Sen. John Fetterman, D-Pa., discusses his experience with anti-obesity medication, Mounjaro (tirzepatide) in a New York Times op-ed.

ThePatriotLight - How GLP-1 drugs were discovered and developed? By Investing.com

ThePatriotLight - How GLP-1 drugs were discovered and developed?How GLP-1 drugs were discovered and developed? By Investing.com

Diabetes and weight-loss drug ‘changed my life,’ says senator: ‘I feel a decade younger’

A U.S. senator said a GLP-1 drug changed his life — and now he's calling for widespread access to anti-obesity medications. Doctors shared thoughts on the potential benefits.

Scientists Just Uncovered A Major Alzheimer's Finding—And It Involves Ozempic

New research finds that GLP-1 receptor agonist medications like Ozempic may help lower your Alzheimer's risk. What doctors want you to know about the new study.

Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities

Glucagon-like peptide-1 (GLP-1) analogs are approved for the treatment of obesity in adults and adolescents. Reports have emerged that the weight loss effect of these medications may be related to changes in food preferences and ingestive behaviors following the treatment. Understanding the mechanisms which impact ingestive behavior could expand opportunities to develop more refined and personalized treatment options for obesity. Recent studies …

Sen. Fetterman urges Trump not to abandon plan for Medicare, Medicaid coverage of weight-loss drugs

Sen. John Fetterman calls for affordable access to GLP-1 drugs like Ozempic and Wegovy, in a New York Times column, sharing his own health improvements from Mounjaro while criticizing the halt of expanded Medicare coverage.